The landscape of Medicare Advantage (MA) is currently defined by a high-stakes legal confrontation between the nation’s largest health insurers and the Centers for Medicare & Medicaid Services (CMS). At the heart of this dispute lies the “Star Ratings” system—a metric that is far more than a simple quality score; it is the financial lifeblood of the private Medicare market, determining billions of dollars in annual federal bonus payments.
What began as a single lawsuit filed by Clover Health has metastasized into a systemic legal challenge, threatening to upend how the federal government regulates, evaluates, and compensates private insurers. As insurers like Elevance Health, SCAN Health, and Alignment Health join the fray, the industry is forcing a fundamental reckoning regarding the transparency, consistency, and fairness of CMS’s methodology.
The Core Conflict: Why Star Ratings Matter
For Medicare Advantage plans, a Star Rating—ranging from one to five—is the primary determinant of financial viability and market competitiveness. Plans that achieve a rating of four stars or higher are eligible for Quality Bonus Payments (QBPs) and can offer enhanced benefits to attract enrollees.
The methodology used by the CMS to determine these ratings is notoriously complex, involving dozens of quality and performance measures. Because these ratings directly correlate to massive financial incentives, even a fractional decline in a score can translate into tens or hundreds of millions of dollars in lost revenue.
The current controversy stems from the CMS’s calculation of 2026 star ratings. Insurers argue that the agency employed arbitrary metrics that unfairly penalized their performance, leading to a "plummeting" of ratings that they claim are disconnected from actual clinical outcomes.
Chronology of a Regulatory Standoff
November 2023: The Opening Salvo
Clover Health filed its initial lawsuit against the CMS, challenging the methodology used to calculate its 2026 Star Ratings. Clover alleged that the agency improperly factored in 20 specific metrics, which the company argued were statistically flawed and resulted in a significant downgrade for its largest plan. Clover estimated that the regulatory decision cost the company $120 million in bonus payments.
May 2024: A Judicial Turning Point
U.S. District Judge John Wood issued a pivotal ruling in favor of Clover Health. The court found that the CMS’s methodology for the disputed measures lacked a sufficient rational basis. The judge ordered the agency to recalculate Clover’s Star Ratings, explicitly excluding the contested metrics that had dragged the plan’s performance down.
October 2024: The Industry-Wide Ripple Effect
Recognizing the implications of the Clover ruling, the CMS announced it would undertake a broader recalculation of MA Star Ratings for the entire industry. However, the agency’s execution of this promise triggered immediate backlash. While the CMS complied with the court’s order for Clover, it continued to apply some of the same contested methodologies to other insurers.
November 2024: The Floodgates Open
The CMS’s decision to apply inconsistent methodologies prompted a wave of litigation. Major players—including Elevance Health, SCAN Health, and Alignment Health—filed lawsuits, arguing that the “Clover precedent” should be applied universally. These insurers contend that the CMS is effectively picking winners and losers by failing to apply the same rigorous standard of calculation across the entire industry.
Supporting Data: The Financial Stakes
The figures cited in these lawsuits provide a clear picture of why insurers are willing to spend millions in legal fees to challenge the federal government. For large-scale health systems, the Star Rating is not just a marketing tool; it is a fundamental component of the corporate balance sheet.
- Elevance Health: The insurance giant has claimed that the CMS’s recalculation methodology deprived the company of approximately $115 million in projected revenue.
- SCAN Health: In its filing, the organization argued that the methodology caused a loss of $125 million in bonus payments.
- Alignment Health: The company reported an estimated $50 million loss in bonus revenue due to the contested ratings.
These figures illustrate a combined impact of hundreds of millions of dollars across just a handful of firms. When projected across the entire Medicare Advantage market, the total financial discrepancy created by the CMS’s contested methodology reaches into the billions.
Official Responses and Institutional Stances
The CMS has remained largely tight-lipped regarding the ongoing litigation, citing agency policy not to comment on active court cases. However, their actions in the courtroom and through regulatory filings suggest a defense built on the premise of "administrative deference"—the idea that federal agencies should be granted wide latitude in interpreting and applying complex regulatory frameworks.
Conversely, the plaintiffs have been vocal. A Clover Health spokesperson provided a statement defending the company’s position:
"While we are restricted in our ability to comment because we are in litigation, what we can say is that we believe that Judge Wood’s decision was thorough and well-reasoned and should be upheld. We will vigorously defend the Company’s rights as we continue in our mission to bring affordable, high-quality care to all seniors on Medicare."
The industry’s collective argument is that the CMS’s methodology is not just "unreasonable," but that it violates the Administrative Procedure Act (APA). They argue that the agency’s failure to provide a transparent, consistent, and logical basis for its metrics violates the standard of "reasoned decision-making" required of federal agencies.
Implications: The Future of Medicare Advantage
The current legal standoff has profound implications for the future of the Medicare program.
1. Increased Scrutiny of CMS Authority
For years, the CMS has operated with significant autonomy in designing the Star Rating system. The success of the Clover Health lawsuit proves that the judiciary is willing to intervene when agencies fail to provide a rigorous, data-driven justification for their methodologies. This could signal an era of increased judicial oversight for federal health agencies.
2. The Risk of Regulatory Instability
If the courts continue to rule in favor of insurers, the CMS may be forced to completely overhaul the way it measures health plan performance. While this could lead to a more "fair" system for insurers, it also risks creating a period of regulatory instability where bonus payments and consumer benefits remain in flux for years.
3. Impact on Consumer Benefits
The Star Rating system was designed to reward plans that provide high-quality care, allowing them to reinvest bonus dollars into lower premiums, extra dental/vision coverage, and wellness programs. If insurers lose hundreds of millions of dollars due to disputed metrics, those losses inevitably trickle down to the enrollees. Beneficiaries may see benefit reductions or premium hikes if the insurers’ financial projections are permanently hampered by these rating drops.
4. A Precedent for Future Disputes
The success of this litigation provides a blueprint for other insurers to challenge CMS decisions. In the past, companies might have viewed the CMS as an untouchable authority. Now, the "Clover model" has established that through persistent, well-funded legal challenges, the industry can force the federal government to the negotiating table.
Conclusion
The legal battle between Clover Health, its industry peers, and the CMS is a watershed moment for the healthcare sector. It highlights the tension between the government’s desire for stringent, outcomes-based regulation and the insurers’ demand for mathematical transparency and fairness.
As these cases wind through the federal court system, the ultimate resolution will determine not only the financial health of the nation’s largest insurers but also the quality and affordability of care for millions of Medicare Advantage enrollees. Whether the judiciary forces the CMS to adopt a more collaborative and transparent approach to metric development remains to be seen, but one thing is clear: the status quo of the Medicare Advantage Star Rating system has been permanently disrupted.
The industry is watching closely, waiting to see if the CMS will double down on its methodology or pivot toward a more conciliatory regulatory stance. For now, the only certainty is that the courtroom—rather than the clinical setting—has become the most critical arena for the future of Medicare Advantage.
